DNA Methylation: Its Role in Cancer Development and Therapy

Current Problems in Cancer

Volumn 32, Issue 5, 2008, Pages 187-235

  Kurkjian, C ^a   Kummar, S ^a   Murgo, A J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZA 001; AZACITIDINE; BIOLOGICAL MARKER; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; FAZARABINE; FLUCYTOSINE DEOXYRIBOSIDE; IMATINIB; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADD ON THERAPY; ALCOHOL CONSUMPTION; ARTICLE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DISEASE COURSE; DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; FATIGUE; HEAD AND NECK CARCINOMA; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONHUMAN; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

AGING; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL TRANSFORMATION, NEOPLASTIC; DISEASE; DNA METHYLATION; DNA MODIFICATION METHYLASES; HISTONE ACETYLTRANSFERASES; HUMANS; INFLAMMATION; NEOPLASMS; PROTEIN METHYLTRANSFERASES; TUMOR MARKERS, BIOLOGICAL;

EID: 52949144622     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2008.08.002     Document Type: Article

References (256)

1. Issa J.P., Ahuja N., Toyota M., Bronner M.P., and Brentnall T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61 (2001) 3573-3577
2. Henderson J.P., Byun J., Williams M.V., McCormick M.L., Parks W.C., Ridnour L.A., et al. Bromination of deoxycytidine by eosinophil peroxidase: a mechanism for mutagenesis by oxidative damage of nucleotide precursors. Proc Natl Acad Sci U S A 98 (2001) 1631-1636
3. Whiteman M., Jenner A., and Halliwell B. Hypochlorous acid-induced base modifications in isolated calf thymus DNA. Chem Res Toxicol 10 (1997) 1240-1246
4. Valinluck V., and Sowers L.C. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res 67 (2007) 5583-5586
5. Forman D., Newell D.G., Fullerton F., Yarnell J.W., Stacey A.R., Wald N., et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. Br Med J 302 (1991) 1302-1305
6. Hansen S., Melby K.K., Aase S., Jellum E., and Vollset S.E. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol 34 (1999) 353-360
7. Nomura A., Stemmermann G.N., Chyou P.H., Kato I., Perez-Perez G.I., and Blaser M.J. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325 (1991) 1132-1136
8. Parsonnet J., Friedman G.D., Vandersteen D.P., Chang Y., Vogelman J.H., Orentreich N., et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325 (1991) 1127-1131
9. Maekita T., Nakazawa K., Mihara M., Nakajima T., Yanaoka K., Iguchi M., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12 (2006) 989-995
10. Fuccio L., Zagari R.M., Minardi M.E., and Bazzoli F. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 25 (2007) 133-141
11. Moayyedi P., Wason C., Peacock R., Walan A., Bardhan K., Axon A.T., et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 5 (2000) 206-214
12. Zerbib F., Lenk C., Sawan B., Cayla R., Broutet N., Carles B., et al. Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients. Eur J Gastroenterol Hepatol 12 (2000) 719-725
13. Seitz H.K., and Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 7 (2007) 599-612
14. Martinez-Chantar M.L., Garcia-Trevijano E.R., Latasa M.U., Perez-Mato I., Sanchez del Pino M.M., Corrales F.J., et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr 76 (2002) 1177S-1182S
15. Giovannucci E., Rimm E.B., Ascherio A., Stampfer M.J., Colditz G.A., and Willett W.C. Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 87 (1995) 265-273
16. Cole B.F., Baron J.A., Sandler R.S., Haile R.W., Ahnen D.J., Bresalier R.S., et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. J Am Med Assoc 297 (2007) 2351-2359
17. Nakagawa H., Nuovo G.J., Zervos E.E., Martin Jr. E.W., Salovaara R., Aaltonen L.A., et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 61 (2001) 6991-6995
18. Albitar M., Manshouri T., Shen Y., Liu D., Beran M., Kantarjiran H.M., et al. Myelodysplastic syndrome is not merely "preleukemia. " Blood 100 (2002) 791-798
19. Ma X., Does M., Raza A., and Mayne S.T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109 (2007) 1536-1542
20. Lai F., Godley L.A., Joslin J., Fernald A.A., Liu J., Espinosa R., et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 71 (2001) 235-245
21. Le Beau M.M., Albain K.S., Larson R.A., Vardiman J.W., Davis E.M., Blough R.R., et al. Clinical and cytogenetic correlations in 63 patients with therapy- related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4 (1986) 325-345
22. Boumber Y.A., Kondo Y., Chen X., Shen L., Gharibyan V., Konishi K., et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 67 (2007) 1997-2005
23. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., et al. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91 (1998) 2985-2990
24. Tien H.-F., Tang J.-L., Tsay W., Liu M.-C., Lee F.-Y., Wang C.-H., et al. Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 112 (2001) 148-154
25. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 (1996) 9821-9826
26. Herman J.G., Civin C.I., Issa J.-P.J., Collector M.I., Sharkis S.J., and Baylin S.B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57 (1997) 837-841
27. Melki J.R., Vincent P.C., and Clark S.J. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59 (1999) 3730-3740
28. Issa J.-P.J., Zehnbauer B.A., Civin C.I., Collector M.I., Sharkis S.J., Davidson N.E., et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 56 (1996) 973-977
29. Liu Z.-J., Zhang X.-B., Zhang Y., and Yang X. Progesterone receptor gene inactivation and CpG island hypermethylation in human leukemia cancer cells. FEBS Lett 567 (2004) 327-332
30. Scardocci A., Guidi F., D'Alo F., Gumiero D., Fabiani E., Diruscio A., et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer 95 (2006) 1108-1113
31. Furukawa Y., Sutheesophon K., Wada T., Nishimura M., Saito Y., Ishii H., et al. Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res 3 (2005) 325-334
32. Ponder B.A.J. Cancer genetics. Nature 411 (2001) 336-341
33. Garcia-Manero G., Daniel J., Smith T.L., Kornblau S.M., Lee M.-S., Kantarjian H.M., et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8 (2002) 2217-2224
34. Corn P.G., Smith B.D., Ruckdeschel E.S., Douglas D., Baylin S.B., and Herman J.G. E-Cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clin Cancer Res 6 (2000) 4243-4248
35. Roman-Gomez J., Jimenez-Velasco A., Barrios M., Prosper F., Heiniger A., Torres A., et al. Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk Lymphoma 48 (2007) 1269-1282
36. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Agirre X., Barrios M., Navarro S., et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104 (2004) 2492-2498
37. Taylor K.H., Pena-Hernandez K.E., Davis J.W., Arthur G.L., Duff D.J., Shi H., et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res 67 (2007) 2617-2625
38. Kusy S., Cividin M., Sorel N., Brizard F., Guilhot F., Brizard A., et al. p14ARF, p15INK4b, and p16INK4a methylation status in chronic myelogenous leukemia. Blood 101 (2003) 374-375
39. Zion M., Ben-Yehuda D., Avraham A., Cohen O., Wetzler M., Melloul D., et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 91 (1994) 10722-10726
40. Asimakopoulos F.A., Shteper P.J., Krichevsky S., Fibach E., Polliack A., Rachmilewitz E., et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 94 (1999) 2452-2460
41. Issa J.P., Kantarjian H., Mohan A., O'Brien S., Cortes J., Pierce S., et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 93 (1999) 2075-2080
42. Nguyen T.T., Mohrbacher A.F., Tsai Y.C., Groffen J., Heisterkamp N., Nichols P.W., et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood 95 (2000) 2990-2992
43. Melki J.R., Vincent P.C., Brown R.D., and Clark S.J. Hypermethylation of E-cadherin in leukemia. Blood 95 (2000) 3208-3213
44. Crossen P.E., and Morrison M.J. Hypermethylation of the M27beta (DXS255) locus in chronic B-cell leukaemia. Br J Haematol 100 (1998) 191-193
45. Rush L.J., and Plass C. Restriction landmark genomic scanning for DNA methylation in cancer: past, present, and future applications. Anal Biochem 307 (2002) 191-201
46. Rush L.J., Raval A., Funchain P., Johnson A.J., Smith L., Lucas D.M., et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 64 (2004) 2424-2433
47. Liu T.-H., Raval A., Chen S.-S., Matkovic J.J., Byrd J.C., and Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res 66 (2006) 653-658
48. Aaltonen L.A., Peltomaki P., Leach F.S., Sistonen P., Pylkkanen L., Mecklin J.P., et al. Clues to the pathogenesis of familial colorectal cancer. Science 260 (1993) 812-816
49. Thibodeau S.N., Bren G., and Schaid D. Microsatellite instability in cancer of the proximal colon. Science 260 (1993) 816-819
50. Herman J.G., Umar A., Polyak K., Graff J.R., Ahuja N., Issa J.-P.J., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95 (1998) 6870-6875
51. Bettstetter M., Dechant S., Ruemmele P., Grabowski M., Keller G., Holinski-Feder E., et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 13 (2007) 3221-3228
52. Watanabe T., Kobunai T., Toda E., Yamamoto Y., Kanazawa T., Kazama Y., et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res 66 (2006) 9804-9808
53. Wang Y.C., Lu Y.P., Tseng R.C., Lin R.K., Chang J.W., Chen J.T., et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 111 (2003) 887-895
54. Xinarianos G., Liloglou T., Prime W., Maloney P., Callaghan J., Fielding P., et al. hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res 60 (2000) 4216-4221
55. Hsu H.-S., Wen C.-K., Tang Y.-A., Lin R.-K., Li W.-Y., Hsa W.-H., et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res 11 (2005) 5410-5416
56. Strathdee G., MacKean M.J., Illand M., and Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18 (1999) 2335-2341
57. Gifford G., Paul J., Vasey P.A., Kaye S.B., and Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10 (2004) 4420-4426
58. Wei M., Grushko T.A., Dignam J., Hagos F., Nanda R., Sveen L., et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65 (2005) 10692-10699
59. Baldwin R.L., Nemeth E., Tran H., Shvartsman H., Cass I., Narod S., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60 (2000) 5329-5333
60. Wilcox C.B., Baysal B.E., Gallion H.H., Strange M.A., and DeLoia J.A. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159 (2005) 114-122
61. Wang C., Horiuchi A., Imai T., Ohira S., Itoh K., Nikaido T., et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol 202 (2004) 215-223
62. Seng T.J., Currey N., Cooper W.A., Lee C.S., Chan C., Horvath L., et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer 99 (2008) 375-382
63. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 358 (2008) 1118-1128
64. Gu J., Berman D., Lu C., et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res 12 (2006) 7329-7338
65. Kim D.-H., Nelson H.H., Wiencke J.K., Zheng S., Christiani D.C., Wain J.C., et al. p16INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 61 (2001) 3419-3424
66. Russo A.L., Thiagalingam A., Pan H., Califano J., Cheng K.-H., Ponte J.F., et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 11 (2005) 2466-2470
67. Leach M.O., Boggis C.R., Dixon A.K., Easton D.F., Eeles R.A., Evans D.G., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365 (2005) 1769-1778
68. Johnson-Maddux A., Ashfaq R., Cler L., Naftalis E., Leitch A.M., Hoover S., et al. Reproducibility of cytologic atypia in repeat nipple duct lavage. Cancer 103 (2005) 1129-1136
69. Suijkerbuijk K.P.M., van der Wall E., Vooijs M., and van Diest P.J. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology 75 (2008) 149-152
70. Belinsky S.A., Liechty K.C., Gentry F.D., Wolf H.J., Rogers J., Vu K., et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 66 (2006) 3338-3344
71. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60 (2000) 5954-5958
72. Zhang Y.-J., Wu H.-C., Shen J., Ahsan H., Tsai W.Y., Yang H.-I., et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 13 (2007) 2378-2384
73. Stupp R., Mason WP, van den Bent M.J., Weller M., Fisher B., Taphoorn M.J.B., et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med 352 (2005) 987-996
74. Hegi M.E., Diserens A.-C., Gorlia T., Hamou M.-F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
75. Brandes A.A., Franceschi E., Tosoni A., Blatt V., Pession A., Tallini G., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26 (2008) 2192-2197
76. Levin B., Lieberman D.A., McFarland B., Smith R.A., Brooks D., Andrews K.S., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58 (2008) 130-160
77. Huang Z.H., Li L.H., Yang F., and Wang J.F. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol 13 (2007) 950-954
78. Lecomte T., Berger A., Zinzindohoue F., Micard S., Landi B., Blons H., et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 100 (2002) 542-548
79. Ito S., Nakayama H., Kodera Y., Ito K., Akiyama S., and Nakao A. Detection of tumor DNA in serum of colorectal cancer patients. Jpn J Cancer Res 93 (2002) 1266-1269
80. Zou H.-Z., Yu B.-M., Wang Z.-W., Sun J.-Y., Cang H., Gao F., et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 8 (2002) 188-191
81. Nakayama H., Hibi K., Takase T., Yamazaki T., Kasai Y., Ito K., et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 105 (2003) 491-493
82. Aggerholm A., Holm M.S., Guldberg P., Olesen L.H., and Hokland P. Promoter hypermethylation of p15INK4B. HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 76 (2006) 23-32
83. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006) 1794-1803
84. Ganser A.H.G., Heil G., Seipelt G., Hofmann W., Fischer J.T., Langer W., et al. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML). Ann Hematol 79 (2000) 30-35
85. de Witte T.M., Suciu S., Peetermans M., Fenaux P., Strijckmans P., Hayat M., et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisationi for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9 (1995) 1805-1811
86. Agrawal S., Unterberg M., Koschmieder S., zur Stadt U., Brunnberg U., Verbeek W., et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res 67 (2007) 1370-1377
87. Jones P.A., and Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20 (1980) 85-93
88. Baylin S.B. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (2005) S4-S11 (suppl 1).
89. Glover A.B., Leyland-Jones B.R., Chun H.G., Davies B., and Hoth D.F. Azacitidine: 10 years later. Cancer Treat Rep 71 (1987) 737-746
90. Silverman L.R., Holland J.F., Weinberg R.S., Alter B.P., Davis R.B., Ellison R.R., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitor hematopoiesis in patienst with myelodysplastic syndromes. Leukemia 7 (1993) 21-29
91. Silverman L.H.J., Demakos E., et al. Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol 68 (1994) A12
92. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissiq R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429-2440
93. Kornblith A.B., Herndon II J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20 (2002) 2441-2452
94. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24 (2006) 3895-3903
95. Marcucci G., Silverman L., Eller M., Lintz L., and Beach C.L. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 45 (2005) 597-602
96. Lyons R.M., Cosgriff T., Modi S., McIntyre H., Fernando I., Backstrom J., et al. Results of the initial treatment phase of a study of three alternative dosing schedules of azacitidine (Vidaza(R)) in patients with myelodysplastic syndromes (MDS). ASH Annual Meeting Abstr 110 (2007) 819
97. Fenaux P., Mufti G.J., Santini V., Finelli C., Giagounidis A., et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 Phase III study. ASH Annual Meeting Abstr 110 (2007) 817
98. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 419-425
99. List A.F., Fenaux P., Mufti G.J., Hellström-Lindberg E., Gore S., Bennett J.M., et al. Effect of azacitidine on overall survival in higher-risk myelodysplastic syndromes without complete remission. J Clin Oncol 26 (2008) 7006
100. Karon M., Sieger L., Leimbrock S., Finklestein J.Z., Nesbit M.E., and Swaney J.J. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 42 (1973) 359-365
101. Kalwinsky D.K., Dahl G.V., Mirro J., Jackson C.W., and Look A.T. Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine. Med Pediatr Oncol 14 (1986) 245-250
102. Steuber C.P., Krischer J., Holbrook T., Camitta B., Land V., Sexauer C., et al. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 14 (1996) 1521-1525
103. Sudan N., Rossetti J.M., Shadduck R.K., Latsko J., Lech J.A., Kaplan R.B., et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 107 (2006) 1839-1843
104. Al-Ali H.K., Schwind S., Becker C., Mueller C., and Niederwieser D. 5-Azacitidine induces hematologic responses in a high proportion of patients with acute myeloid leukaemia refractory to or not eligible for intensive chemotherapy. ASH Annual Meeting Abstr 108 (2006) 1953
105. Goldberg S.L., Hsu J.W., Orr A.R., Rowley S.D., Donato M.L., McKiernan P., et al. 5-Azacitidine therapy in elderly patients with acute myelogenous leukemia yields similar survival compared to 3+7 induction chemotherapy with less transfusional support, bacteremias, and hospital days. ASH Annual Meeting Abstr 108 (2006) 4569
106. Nand S., Godwin J., Smith S., Barton K., Germano E., and Stiff P. Azacitidine plus gemtuzumab ozogamicin (GO): a novel combination in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly. ASH Annual Meeting Abstr 108 (2006) 1981
107. Quagliana J.M., O'Bryan R.M., Baker L., Gottlieb J., Morrison F.S., Eyre H.J., et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep 61 (1977) 51-54
108. Weiss A.J., Metter G.E., Nealon T.F., Keanan J.P., Ramirez G., Swaiminathan A., et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep 61 (1977) 55-58
109. Bast R.C.L.R., and Hu W. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. J Clin Oncol 26 (2008) 3500
110. Jarrard D.F., Kinoshita H., Shi Y., Sandefur C., Hoff D., Meisner L.F., et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58 (1998) 5310-5314
111. Sonpavde G.A.A., Delaune R., Garbo L.E., Rousey R.E., Weinstein R.E., et al. Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade. J Clin Oncol 26 (2008) 5172
112. de Vos D., and van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol 84 suppl 1 (2005) 3-8
113. Pliml J.S.F. Synthesis of 2′-deoxy-D-ribofuranosyl-5-azacytosine. Coll Czeck Chem Commun 29 (1964) 2576-2577
114. Wijermans P.W., Krulder J.W., Huijgens P.C., and Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11 (1997) 1-5
115. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18 (2000) 956-962
116. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (2004) 1635-1640
117. Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 (2007) 52-57
118. Ruter B., Wijermans P.W., and Lubbert M. Superiority of prolonged low-dose azanucleoside administration?. Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer 106 (2006) 1744-1750
119. Borthakur G., Ahdab S.E., Ravandi F., Faderl S., Ferrajoli A., Newman B., et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49 (2008) 690-695
120. Momparler R.L., Rivard G.E., and Gyger M. Clinical trial on 5-AZA-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30 (1985) 277-286
121. Ravandi F., Kantarjian H., Cohen A., Davis M., O'Brien S., Anderlini P., et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27 (2001) 1221-1225
122. de Lima M., Ravandi F., Shahjahan M., Andersson B., Couriel D., Donato M., et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97 (2003) 1242-1247
123. Kantarjian H.M., O'Brien S.M., Keating M., Bennett J.M., Albitar M., DiPersio J., et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11 (1997) 1617-1620
124. Kantarjian H.M., O'Brien S., Cortes J., Giles F.J., Faderl S., Issa J.P., et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98 (2003) 522-528
125. Issa J.-P.J., Gharibyan V., Cortes J., Jelinek J., Morris G., Verstovsek S., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23 (2005) 3948-3956
126. La Rosee P., Johnson K., Corbin A.S., Stoffregen E.P., Moseson E.M., Willis S., et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 103 (2004) 208-215
127. Oki Y., Kantarjian H.M., Gharibyan V., Jones D., O'Brien S., Verstovsek S., et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109 (2007) 899-906
128. van Groeningen C.J., Leyva A., O'Brien A.M.P., Gall H.E., and Pinedo H.M. Phase I and pharmacokinetic study of 5-Aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46 (1986) 4831-4836
129. Abele R., Clavel M., Dodion P., Bruntsch U., Gundersen S., Smyth J., et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 23 (1987) 1921-1924
130. Clavel M., Monfardini S., Fossa S., Smyth J., Renard J., and Kaye S.B. 5-Aza-2′-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol 3 (1992) 399-400
131. Sessa C., ten Bokkel Huinink W., Stoter G., Renard J., and Cavalli F. Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group. Eur J Cancer 26 (1990) 137-138
132. Thibault A., Figg W.D., Bergan R.C., Lush R.M., Myers C.E., Tompkins A., et al. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84 (1998) 87-89
133. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., and Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8 (1997) 358-368
134. Abbruzzese J.L., and Frost P. Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol 30 (1992) 31-36
135. Lenzi R., Frost P., and Abbruzzese J.L. Modulation of cisplatin resistance by 2′-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res 14 (1994) 247-251
136. Schwartsmann G., Schunemann H., Gorini C.N., Filho A.F., Garbino C., Sabini G., et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 18 (2000) 83-91
137. Aparicio A., Eads C.A., Leong L.A., Laird P.W., Newman E.M., Synold T.W., et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 51 (2003) 231-239
138. Samlowski W.E., Leachman S.A., Wade M., Cassidy P., Porter-Gill P., Busby L., et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 23 (2005) 3897-3905
139. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12 (2006) 5777-5785
140. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1 (1995) 686-692
141. Stockert E., Jager E., Chen Y.T., Scanlan M.J., Gout I., Karbach J., et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187 (1998) 1349-1354
142. Tureci O., Mack U., Luxemburger U., Heinen H., Krummenauer F., Sester M., et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 236 (2006) 64-71
143. Driscoll J.S., Marquez V.E., Plowman J., Liu P.S., Kelley J.A., and Barchi Jr. J.J. Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem 34 (1991) 3280-3284
144. McCormack P.L., and Palmer D.G. Sulphydryl dependence of the inhibition of mitogen-induced human lymphocyte proliferation by sodium aurothiomalate. Biochem Pharmacol 29 (1980) 3333-3336
145. Cheng J.C., Matsen C.B., Gonzales F.A., Ye W., Greer S., Marquez V.E., et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95 (2003) 399-409
146. Yoo CB, Chuang JC, Byun H-M, Egger G, Yang AS, Dubeau L, et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res 2008:1940-6207.CAPR-1907-0008.
147. Holleran J.L., Parise R.A., Joseph E., Eiseman J.L., Covey J.M., Glaze E.R., et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 11 (2005) 3862-3868
148. Newman E.M., and Santi D.V. Metabolism and mechanism of action of 5-fluorodeoxycytidine. Proc Natl Acad Sci U S A 79 (1982) 6419-6423
149. Kaysen J., Spriggs D., and Kufe D. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. Cancer Res 46 (1986) 4534-4538
150. Beumer J.H., Parise R.A., Newman E.M., Doroshow J.H., Synold T.W., Lenz H.J., et al. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol 62 (2008) 363-368
151. Byun H.M., Choi S.H., Laird P.W., Trinh B., Siddiqui M.A., Marquez V.E., et al. 2′-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett 266 (2008) 238-248
152. Brueckner B., Garcia Boy R., Siedlecki P., Musch T., Kliem H.C., Zielenkiewicz P., et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res 65 (2005) 6305-6311
153. Stresemann C., Brueckner B., Musch T., Stopper H., and Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66 (2006) 2794-2800
154. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., and Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140 (1988) 2197-2200
155. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., et al. Tea polyphenol (-)-epigallocatechin-3-Gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 63 (2003) 7563-7570
156. Chuang J.C., Yoo C.B., Kwan J.M., Li T.W.H., Liang G., Yang A.S., et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 4 (2005) 1515-1520
157. Momparler RL. Cancer epigenetics. Oncogene 22:6479-83.
158. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 16 (2002) 6-21
159. Bird A.P., and Wolffe A.P. Methylation-induced repression- belts, braces, and chromatin. Cell 99 (1999) 451-454
160. Fahrner J.A., Eguchi S., Herman J.G., and Baylin S.B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 62 (2002) 7213-7218
161. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 (2001) 1074-1080
162. Jones P.L., Jan Veenstra G.C., Wade P.A., et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19 (1998) 187-191
163. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., and Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21 (1999) 103-107
164. Gagnon J., Shaker S., Primeau M., Hurtubise A., and Momparler R.L. Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs 14 (2003) 193-202
165. Primeau M., Gagnon J., and Momparler R.L. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2prime-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103 (2003) 177-184
166. Gore S.D., Baylin S., Sugar E., Carraway H., Miller C.B., Carducci M., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66 (2006) 6361-6369
167. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20 (2001) 6969-6978
168. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., and Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276 (2001) 36734-36741
169. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108 (2006) 3271-3279
170. Blum W., Klisovic R.B., Hackanson B., Liu Z., Liu S., Devine H., et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25 (2007) 3884-3891
171. Garcia-Manero G., Yang H., Bueso-Ramos C., Ferrajoli A., Cortes J., Wierda W.G., et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111 (2008) 1060-1066
172. Weiser T.S., Guo Z.S., Ohnmacht G.A., Parkhurst M.L., Tong-On P., Marincola F.M., et al. Sequential 5-aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 24 (2001) 151-161
173. Silverman L.R., Verma A., Odchimar-Reissig R., Cozza A., Najfeld V., and Licht J.D. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. J Clin Oncol 26 (2008) 7000
174. Yee K.W.L., Minden M.D., Brandwein J., Schimmer A., Schuh A., Gupta V., et al. A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia (AML). ASH Annual Meeting Abstr 110 (2007) 908
175. Lin J., Yao D.-m., Qian J., Wang Y.-l., Han L.-x., Jiang Y.-w., et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 32 (2008) 1541-1545
176. Wu Q., Lothe R., Ahlquist T., Silins I., Trope C., Micci F., et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 6 (2007) 45
177. Johan M.F., Bowen D.T., Frew M.E., Goodeve A.C., and Reilly J.T. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 129 (2005) 60-65
178. Ihalainen J.P.S., Savolainen E.R., Janssen S.E., and Palotie A. Hypermethylation of the calcitonin gene in the myelodysplastic syndromes. Leukemia 7 (1993) 263-267
179. Jost E, Schmid J, Wilop S, Schubert C, Suzuki H, Herman JG, et al. Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia. Br J Haematol 2008 [Epub ahead of print].
180. Kroeger H., Jelinek J., Estecio M.R.H., He R., Kondo K., Chung W., et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112 (2008) 1366-1373
181. Hess C.J., Errami A., Berkhof J., Denkers F., Ossenkoppele G.J., Nygren A.O.H., et al. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma 49 (2008) 1132-1141
182. Schmelz K., Wagner M., Dorken B., and Tamm I. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 114 (2005) 683-695
183. Oka T., Ouchida M., Koyama M., Oka T., Ouchida M., Koyama M., et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 62 (2002) 6390-6394
184. Hoshino K., Quintas-Cardama A., Yang H., Sanchez-Gonzalez B., and Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia 21 (2007) 906-911
185. Agirre X., Roman-Gomez J., Vazquez I., Jimenez-Velasco A., Garate L., Montiel-Duarte C., et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 118 (2006) 1945-1953
186. Liu T.C., Lin S.F., Chang J.G., Yang M.Y., Hung S.Y., and Chang C.S. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol 123 (2003) 654-661
187. Nagy E., Beck Z., Kiss A., et al. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer 39 (2003) 2298-2305
188. Roman-Gomez J., Castillejo J.A., Jimenez A., Cervantes F., Boque C., Hermosin L., et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon. Alfa J Clin Oncol 21 (2003) 1472-1479
189. Yang M.-Y., Liu T.-C., Chang J.-G., Lin P.-M., and Lin S.-F. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 101 (2003) 3205-3211
190. Oka T., Ouchida M., Koyama M., Ogama Y., Takada S., Nakatani Y., et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 62 (2002) 6390-6394
191. Shteper P.J., Siegfried Z., Asimakopoulos F.A., Palumbo G.A., Rachmilewitz E.A., Ben-Neriah Y., et al. ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL. Leukemia 15 (2001) 575-582
192. Strathdee G., Holyoake T.L., Sim A., Parker A., Oscier D.G., Melo J.V., et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res 13 (2007) 5048-5055
193. Papageorgiou S.G., Lambropoulos S., Pappa V., Economopoulou C., Kontsioti F., Papageorgiou E., et al. Hypermethylation of the p15INK4B gene promoter in B-chronic lymphocytic leukemia. Am J Hematol 82 (2007) 824-825
194. Motiwala T., Majumder S., Kutay H., Smith D.S., Neuberg D.S., Lucas D.M., et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res 13 (2007) 3174-3181
195. Raval A., Tanner S.M., Byrd J.C., Perko J.D., Chen S.-S., et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 129 (2007) 879-890
196. Petrocca F., Iliopoulos D., Qin H.R., Nicoloso M.S., Yendamuri S., Wojcik S.E., et al. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res 66 (2006) 10287-10291
197. Strathdee G., Sim A., Parker A., Oscier D., and Brown R. Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia 20 (2006) 1326-1329
198. Raval A., Lucas D.M., Matkovic J.J., Bennett K.L., Liyanarachchi S., Young D.C., et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 3877-3885
199. Bechter O.E., Eisterer W., Dlaska M., Kühr T., and Thaler J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol 30 (2002) 26-33
200. Esteller M., Silva J.M., Dominguez G., Bonilla F., Matias-Guiu X., Lerma E., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92 (2000) 564-569
201. Esteller M., Fraga M.F., Guo M., Garcia-Foncillas J., Hedenfalk I., Godwin A.K., et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10 (2001) 3001-3007
202. Watanabe Y., Ueda H., Etoh T., Koike E., Fujinami N., Mitsuhashi A., et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res 27 (2007) 1449-1452
203. Wiley A., Katsaros D., Chen H., Rigault de la Longrais I.A., Beeghly A., Puopolo M., et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107 (2006) 299-308
204. Choi Y.L., Kang S.Y., Shin Y.K., Choi J.S., Kim S.H., Lee S.J., et al. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch 448 (2006) 331-336
205. Makarla P.B., Saboorian M.H., Ashfaq R., Toyooka K.O., Toyooka S., Minna J.D., et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11 (2005) 5365-5369
206. Petrocca F., Iliopoulos D., Qin H.R., et al. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res 66 (2006) 10287-10291
207. Cooper W.N., Dickinson R.E., Dallol A., Grigorieva E.V., Pavlova T.V., Hesson L.B., et al. Epigenetic regulation of the ras effector//tumour suppressor RASSF2 in breast and lung cancer. Oncogene 27 (2007) 1805-1811
208. Toyooka K.O., Toyooka S., Virmani A.K., Sathyanarayana U.G., Euhus D.M., Gilcrease M., et al. Loss of expression and aberrant methylation of the CDH13 (H-Cadherin) gene in breast and lung carcinomas. Cancer Res 61 (2001) 4556-4560
209. Toyooka S., Toyooka K.O., Maruyama R., Virmani A.K., Girard L., Miyajima K., et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 1 (2001) 61-67
210. Machida E.O., Brock M.V., Hooker C.M., Nakayama J., Ishida A., Amano J., et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 66 (2006) 6210-6218
211. Brock M.V., Kim M.P., Hooker C.M., Alberg A.J., Jordan M.M., Roig C.M., et al. Pulmonary resection in octogenarians with stage I nonsmall cell lung cancer: a 22-year experience. Ann Thorac Surg 77 (2004) 271-277
212. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.-P.J., Davidson N.E., et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55 (1995) 4525-4530
213. Vousden K.H. p53: Death Star. Cell 103 (2000) 691-694
214. Rhee I., Bachman K.E., Park B.H., Jair K.-W., Yen R.-W.C., Schuebel K.E., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416 (2002) 552-556
215. Gazzoli I., Loda M., Garber J., Syngal S., and Kolodner R.D. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 62 (2002) 3925-3928
216. Shen L., Kondo Y., Hamilton S.R., Rashid A., and Issa J.-P.J. p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology 124 (2003) 626-633
217. Whitehall V.L.J., Walsh M.D., Young J., Leggett B.A., and Jass J.R. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 61 (2001) 827-830
218. Noetzel E., Veeck J., Niederacher D., Galm O., Horn F., Hartmann A., et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 8 (2008) 154
219. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. 1995;55:4525-30.
220. Droufakou S., Deshmane V., Roylance R., Hanby A., Tomlinson I., and Hart I.R. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 92 (2001) 404-408
221. Sarrio D., Moreno-Bueno G., Hardisson D., Sanchez-Estevez C., Guo M., Herman J.G., et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 106 (2003) 208-215
222. Munot K., Bell S.M., Lane S., Horgan K., Hanby A.M., and Speirs V. Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Hum Pathol 37 (2006) 989-999
223. Xu X.L., Yu J., Zhang H.Y., Sun M.H., Gu J., Du X., et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 10 (2004) 3441-3454
224. Stearns V., Zhou Q., and Davidson N.E. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest 25 (2007) 659-665
225. Lee W.H., Morton R.A., Epstein J.I., Brooks J.D., Campbell P.A., Bova G.S., et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 91 (1994) 11733-11737
226. Hu J.-F., Nguyen P.H., Pham N.V., Vu T.H., and Hoffman A.R. Modulation of Igf2 genomic imprinting in mice induced by 5-azacytidine, an inhibitor of DNA methylation. Mol Endocrinol 11 (1997) 1891-1898
227. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64 (2004) 1975-1986
228. Fu V.X., Schwarze S.R., Kenowski M.L., LeBlanc S., Svaren J., and Jarrard D.F. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. J Biol Chem 279 (2004) 52218-52226
229. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91 (1994) 9700-9704
230. Kagara I., Enokida H., Kawakami K., Matsuda R., Toki K., Nishimura H., et al. CpG hypermethylation of the UCHL1 Gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol 180 (2008) 343-351
231. Kvasha S., Gordiyuk V., Kondratov A., Ugryn D., Zgonnyk Y.M., Rynditch A.V., et al. Hypermethylation of the 5′CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett 265 (2008) 250-257
232. Christoph F., Weikert S., Kempkensteffen C., Krause H., Schostak M., Kollermann J., et al. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res 12 (2006) 5040-5046
233. Gumz M.L., Zou H., Kreinest P.A., Childs A.C., Belmonte L.S., LeGrand S.N., et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13 (2007) 4740-4749
234. Costa V., Henrique R., Ribeiro F., Pinto M., Oliveira J., Lobo F., et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 7 (2007) 133
235. Christoph F., Hinz S., Kempkensteffen C., Schostak M., Schrader M., and Miller K. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype. J Urol 178 (2007) 2655-2659
236. Zhang Q., Ying J., Zhang K., Li H., Ng K.M., Zhao Y., et al. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett 249 (2007) 220-226
237. Okuda H., Toyota M., Ishida W., Furihata M., Tsuchiya M., Kamada M., et al. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene 25 (2005) 1733-1742
238. Fukushima N., Sato N., Ueki T., Su G.H., Hruban R.H., and Goggins M. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 160 (2002) 1573-1581
239. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22:3806-12.
240. Matsubayashi H., Sato N., Fukushima N., Yeo C.J., Walter K.M., Brune K., et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 9 (2003) 1446-1452
241. Fukushima N., Sato N., Sahin F., Su G.H., Hruban R.H., and Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 89 (2003) 338-343
242. Ueki T., Toyota M., Sohn T., Yeo C.J., Issa J.-P.J., Hruban R.H., et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60 (2000) 1835-1839
243. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. 2000;92:564-9.
244. Winter J.M., Ting A.H., Vilardell F., Gallmeier E., Baylin S.B., Hruban R.H., et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 14 (2008) 412-418
245. Dansranjavin T., Mobius C., Tannapfel A., Bartels M., Wittekind C., Hauss J., et al. E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncol Rep 15 (2006) 1125-1131
246. Kang G.H., Lee S., Kim J.S., and Jung H.Y. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 83 (2003) 635-641
247. To K.F., Leung W.K., Lee T.L., Yu J., Tong J.H., Chan M.W., et al. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer 102 (2002) 623-628
248. Seidel C., Bartel F., Rastetter M., Bluemke K., Wurl P., Taubert H., et al. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer 114 (2005) 442-447
249. Kawaguchi K.-i., Oda Y., Saito T., Yamamoto H., Takahira T., Kobayashi C., et al. DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol 19 (2005) 106-114
250. Seidel C., Schagdarsurengin U., Blumke K., Wurl P., Pfeifer G.P., Hauptmann S., et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 46 (2007) 865-871
251. Spugnardi M., Tommasi S., Dammann R., Pfeifer G.P., and Hoon D.S.B. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63 (2003) 1639-1643
252. Hoon D.S.B., Spugnardi M., Kuo C., Huang S.K., Morton D.L., and Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23 (2004) 4014-4022
253. Worm J., Christensen C., Gronbaek K., Tulchinsky E., and Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23 (2004) 5215-5226
254. Fischer J.R., Ohnmacht U., Rieger N., Zemaitis M., Stoffregen C., Kostrzewa M., et al. Promoter methylation of RASSF1A. RAR[beta] and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54 (2006) 109-116
255. Tsou J.A., Shen L.Y.C., Siegmund K.D., Long T.I., Laird P.W., Seneviratne C.K., et al. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 47 (2005) 193-204
256. Hirao T., Bueno R., Chen C.-J., Gordon G.J., Heilig E., and Kelsey K.T. Alterations of the p16INK4 locus in human malignant mesothelial tumors. Carcinogenesis 23 (2002) 1127-1130